HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Peripheral blood stem cell transplantation for non-Hodgkin's lymphoma in complete remission.

Abstract
High-dose chemotherapy with PBSCT as consolidation therapy was administered to 15 patients with non-Hodgkin's lymphoma admitted to our department between November 1991 and March 1998. The average number of CD34-positive cells harvested was 3.1 x 10(6)/kg and the median time to a granulocyte count above 500/microliter was 12.8 days. Of the patients, one died from cytomegalovirus pneumomonia after WBC count recovered, 2 relapsed, and 12 patients are still alive and disease-free. The average disease-free survival period was 50.0 months. Stem cell harvesting is relatively simple and hematopoietic recovery is mory rapid with PBSCT than with ABMT. Our findings suggest that PBSCT can be used for consolidation therapy in NHL patients who have achieved complete remission with standard chemotherapy.
AuthorsT Yamane, M Hino, K Ohta, T Nakao, H Nakamae, R Yamamura, T Takubo, N Tatsumi
JournalOsaka city medical journal (Osaka City Med J) Vol. 44 Issue 2 Pg. 219-23 (Dec 1998) ISSN: 0030-6096 [Print] JAPAN
PMID10097601 (Publication Type: Journal Article)
Topics
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma, Non-Hodgkin (drug therapy, surgery)
  • Male
  • Middle Aged
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: